XBiotech Inc. (NASDAQ:XBIT) Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets raised its stake in shares of XBiotech Inc. (NASDAQ:XBIT) by 184.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 40,040 shares of the biopharmaceutical company’s stock after buying an additional 25,987 shares during the quarter. BNP Paribas Financial Markets’ holdings in XBiotech were worth $310,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of XBIT. Bank of New York Mellon Corp grew its holdings in XBiotech by 102.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 98,314 shares of the biopharmaceutical company’s stock valued at $505,000 after buying an additional 49,863 shares during the last quarter. Rhumbline Advisers grew its holdings in XBiotech by 2,568.5% during the 2nd quarter. Rhumbline Advisers now owns 20,094 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 19,341 shares during the last quarter. American Century Companies Inc. acquired a new stake in XBiotech during the 2nd quarter valued at $393,000. Charles Schwab Investment Management Inc. grew its holdings in XBiotech by 7.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 58,437 shares of the biopharmaceutical company’s stock valued at $452,000 after buying an additional 4,298 shares during the last quarter. Finally, FMR LLC grew its holdings in XBiotech by 34.4% during the 3rd quarter. FMR LLC now owns 28,992 shares of the biopharmaceutical company’s stock valued at $224,000 after buying an additional 7,420 shares during the last quarter. Institutional investors and hedge funds own 55.70% of the company’s stock.

XBiotech Stock Performance

Shares of NASDAQ:XBIT opened at $6.95 on Monday. The business’s fifty day moving average price is $7.13 and its two-hundred day moving average price is $6.70. The stock has a market cap of $211.84 million, a PE ratio of -6.44 and a beta of 1.41. XBiotech Inc. has a one year low of $3.81 and a one year high of $9.96.

XBiotech Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.